PHAI

Pharmachain AI by Virtuals Price Today & AI Analysis

PHAI
Base·AI Analysis
Analysis as of May 2, 2026

$0.042058

+1.20%24h
LiveContract:0x3513e4a7d27d18c2c894d98bc5a55406360b9ba3Chain:BaseHolders:4.3KMarket cap:$20.58KLiquidity:$9.03K

More tokens on Base

aeonbook

aeonbook

aeonbook

$0.0766161.1%
MC $6.6K
smolvm

smolvm

smolvm

$0.0626621.5%
MC $26.6K
COMMON

COMMON

COMMON

$0.0455283.8%
MC $552.8K
O

ODYSSEUS

Odysseus

$0.0629011.8%
MC $29.0K
SIMMI

SIMMI

Simmi Token

$0.0532410.1%
MC $324.1K
GOOGLc

GOOGLc

Alphabet Inc.

$343.521.5%
MC $2.18M

Advanced charting powered by TradingView

Continue in chat

Ask Unhosted AI about PHAI

What's Twitter saying?

Sentiment, KOL mentions, top tweets

Whale activity

Who is accumulating or distributing

What are the risks?

Red flags, security, concentration

Should I buy?

Bull case, bear case, entry / exit

Movement since reportreport from May 2, 2026, 09:01 PM UTC
Market Cap

$55.71K

24h Volume

$96.55K

Liquidity

$49.24K

FDV

—

Holders

4.1K

24HLoading trading activity…

Holder Insights

Live

Total holders

—

AI Executive Summary

Pharmachain AI (PHAI) is an early-stage AI utility token targeting pharmaceutical supply chain optimization through real-time inventory tracking and shortage prediction. The token addresses a genuine $1.65 trillion market problem with documented inefficiencies, but currently shows critical structural weaknesses including extreme holder concentration (100% in top 10), minimal liquidity ($49K), and no verifiable project traction. The recent 263% price surge appears driven by speculative trading rather than fundamental adoption, with concerning distribution patterns suggesting potential pump-and-dump dynamics.

Figures cited above are from the market snapshot taken when this analysis ran — May 2, 2026, 09:01 PM UTC. Live values may differ; the key facts at the top of the page are current.

Risk: very_high
Sentiment: bearish
Targets underserved pharmaceutical supply chain problem with documented FDA shortage crisis
Combines AI-driven inventory optimization with shortage prediction capabilities
Addresses both developed markets (US: 41K pharmacies, 340M people) and emerging markets (Africa: 4.5K pharmacies, 200M people) with severe distribution gaps

Pharmachain AI by Virtuals AI Price Analysis

Low Confidence
Short-Term24h-7d
Bearish

PHAI has experienced explosive 263% gains in 24 hours, indicating a parabolic move that typically precedes sharp corrections. The 55.8% buy pressure is being offset by concerning holder concentration (100% in top 10), suggesting limited organic demand. Short-term price action is likely to consolidate or retrace as early buyers take profits.

Medium-Term30d-90d
Neutral

Medium-term outlook depends entirely on project execution and holder distribution normalization. If the team successfully addresses concentration risk and demonstrates real pharmaceutical supply chain integration, the token could stabilize and build. However, without significant fundamental progress and retail adoption, the token faces structural headwinds from its current distribution model.

Bullish Factors
  • +Addresses massive $1.65T pharmaceutical market with documented inefficiencies in drug distribution
  • +Real problem statement: FDA lists hundreds of essential medicines in shortage while identical drugs expire elsewhere
  • +Strong conceptual value proposition: real-time pharmacy inventory + shortage prediction could save billions in losses
  • +Buy pressure at 55.8% with 164 buy transactions vs 166 sell transactions shows relatively balanced participation
  • +Holder growth of 35 new holders in 24h (0.85%) indicates ongoing interest despite parabolic move
  • +Contract verified on-chain, reducing smart contract risk
Bearish Factors
  • -Critical concentration risk: Top 10 holders control 100% of supply, top 100 holders control 100% - this is a massive red flag for manipulation and exit liquidity
  • -Extremely shallow liquidity at only $49,235 USD - any significant sell pressure will cause severe slippage and price collapse
  • -Market cap of only $55,714 with fully diluted valuation of $129,437 suggests minimal real adoption or utility
  • -263% 24-hour gain is unsustainable parabolic move typical of pump-and-dump patterns, not organic growth
  • -Security score of 47/100 indicates moderate-to-high smart contract risk despite verification
  • -No evidence of actual pharmaceutical partnerships, pilot programs, or real-world implementation
  • -Retail holders represent ~0% of supply - 416 octopus holders (<$1K each) own negligible amounts while whales dominate
  • -3,736 holders acquired via transfer (90.5% of acquisition method) rather than organic swaps (6.9%), suggesting airdrop/distribution scheme
  • -Only 105 unique buyers in 24h for a token with 4,124 holders indicates low organic trading activity

Disclaimer: This AI-generated prediction is for informational purposes only and does not constitute financial advice. Cryptocurrency investments are highly volatile. Always conduct your own research.

Token Info

ChainBase
Contract0x3513...9ba3
Total Supply—
Decimals—

Key Risks

•Critical concentration risk: 100% of supply in top 10 holders creates single point of failure and extreme exit liquidity risk. Any coordinated whale exit would crash price 80%+.
•Extreme liquidity risk: $49K liquidity is insufficient for meaningful trading. Position sizes above $5-10K will experience severe slippage. This creates a liquidity trap for retail buyers.
•Parabolic price action: 263% 24h gain is unsustainable and typically precedes 50-80% corrections. The pattern suggests we may be near a local top.
•Zero project traction: No evidence of pharmaceutical partnerships, pilot programs, or real-world implementation. The token is purely speculative with no fundamental support.

Trading Insight

bearish

Despite positive buy pressure (55.8%), trading sentiment is bearish due to parabolic price action, extreme concentration, and low participation breadth. The 330 total transactions in 24h across 4,124 holders (8% participation rate) indicates most holders are passive, not active traders. This suggests limited organic demand and high vulnerability to coordinated selling.

AI-generated insight. Not financial advice.

Frequently Asked Questions

Trend Analysis

Short-Term (7d):
Bullish
Medium-Term (30d):
Neutral

Short-term trend is strongly upward with 263% 24h gains, but this is a parabolic move characteristic of unsustainable rallies. The 4-hour gain of 205% and 1-hour gain of 32% show acceleration into the move, which typically precedes reversal. Medium-term trend is likely to be sideways consolidation or downtrend as the market reprices after the initial spike.

Momentum

Status:
Overbought

Extreme overbought conditions indicated by 263% 24h move with minimal volume ($96.5K total). The 5-minute change of 0% after such explosive moves suggests momentum is exhausting. Overbought conditions typically resolve through either consolidation or sharp correction. The buy pressure of 55.8% is elevated but not extreme, suggesting some sellers are already taking profits.

Volume Analysis

Buy 55.8%Sell 44.2%

Volume Trend: Increasing

Volume trend shows recent acceleration with 4-hour volume comparable to 24-hour volume, indicating buying pressure is concentrating into recent candles. However, absolute volume of $96.5K in 24h is extremely thin for a token with $55K market cap - this represents only 1.7x market cap in daily volume, which is low. The increasing trend is concerning because it's driving parabolic price action on minimal liquidity, creating extreme slippage risk.

Recent Price Action

Classic parabolic spike pattern: 0% (5min) → 32% (1h) → 205% (4h) → 263% (24h). This shows accelerating gains with each timeframe, which is the hallmark of unsustainable moves. The 5-minute stagnation at 0% after the spike suggests momentum is exhausting at current levels.

Parabolic patterns typically resolve through sharp corrections of 50-80% as early buyers take profits and late buyers panic sell. This pattern is historically associated with high-risk, low-liquidity tokens and often precedes significant drawdowns. The pattern suggests we may be near a local top.

Key Price Levels

Support
Immediate$0.00008
Major$0.00004
Resistance
Immediate$0.00020
Major$0.00035

Immediate support at $0.00008 represents a 38% pullback from current levels and would likely hold if profit-taking is orderly. Major support at $0.00004 represents a 69% correction and would likely hold if there's no panic selling. Immediate resistance at $0.00020 is a psychological level that could attract sellers. Major resistance at $0.00035 would represent a 170% move from current levels and is unlikely in near term without fundamental catalyst.

Holder Metrics

Total Holders4,124
24h Change+35
Growth Rate+0.85%

Holder growth is slowing despite price appreciation, with only 0.85% growth in 24h. This suggests the token is not attracting new organic buyers at a rate that would justify the price increase. The stable but slow growth indicates the token has reached most of its initial distribution targets and is now dependent on existing holders for liquidity. This is a bearish signal for long-term sustainability.

Holder Distribution

Top 10 Holders100%
Top 100 Holders100%
Retail Holders0.0%
Concentration Risk:
Critical

This is the most critical finding in the analysis: 100% of PHAI supply is held by the top 10 holders, with the top 100 also holding 100%. This means there is literally zero supply in retail hands. The 4,124 total holders are almost entirely airdrop recipients with negligible token amounts. This distribution structure is fundamentally broken and creates extreme risks: (1) Any top 10 holder can crash the price by selling, (2) There is no organic retail demand to support price, (3) The token is entirely dependent on whale coordination, (4) Exit liquidity is severely constrained. This level of concentration is typically seen in failed tokens or pump-and-dump schemes.

Whale Activity

Sentiment:
Accumulating

Whales are accumulating based on net inflow of $11.3K (20.9% more buys than sells). However, with only $49K total liquidity and 100% concentration, whale 'accumulation' may simply be internal transfers between coordinated parties rather than genuine market buying.

  • •35 whale holders (>$1M each) control 100% of supply - this is the most significant transaction pattern
  • •Net inflow of $11,276 suggests coordinated accumulation, but may be artificial given concentration
  • •164 buy transactions vs 166 sell transactions shows balanced participation but concentrated in whale wallets

Whale activity appears coordinated rather than organic. The perfect 100% concentration suggests this may be a pre-arranged distribution where early backers control all supply. The accumulation pattern could indicate either genuine conviction in the project or preparation for a coordinated exit. Given the lack of project traction and extreme concentration, the latter seems more likely. Whales have complete control over price and can exit at any time, creating severe counterparty risk for retail buyers.

Smart Money Indicators

Confidence:
Low
Profit-Taking Risk:
High

Early buyers (whales) are in extremely profitable positions with 263% gains in 24h. However, their positions are so large relative to liquidity that they cannot exit without crashing the price. This creates a prisoner's dilemma where early buyers are trapped in their positions unless they coordinate an exit or find new buyers to absorb their supply.

Smart money confidence is low because the token shows no evidence of genuine smart money accumulation - instead, it shows signs of coordinated distribution. True smart money would be diversifying into a token with better fundamentals, lower concentration, and more liquidity. The fact that smart money is not entering at these levels (only 105 unique buyers in 24h) suggests they see the risks clearly.

Liquidity Analysis

Total Liquidity$49,235.24
Depth:
Shallow
Slippage Risk:
High

Liquidity is critically shallow at only $49K USD. This means: (1) A $10K sell order would cause 20%+ slippage, (2) A $50K sell order would likely crash the price 80%+, (3) The token is essentially illiquid for any meaningful position sizing. The shallow liquidity combined with 100% concentration means that any whale exit would be catastrophic for price. This is not a tradeable token for position sizes above a few thousand dollars without accepting extreme slippage. The liquidity depth is insufficient to support the current market cap, let alone future growth.

Overall Risk:
Very High
92/100

Risk Breakdown

Volatility
High

263% 24h gain demonstrates extreme volatility. The parabolic price action and thin liquidity create conditions for 50-80% corrections. Volatility is likely to remain extreme until the token either gains real traction or collapses.

Liquidity
High

Only $49K liquidity is critically shallow. Any position above $5-10K will experience severe slippage. Exit liquidity is severely constrained - large holders cannot exit without crashing price. This creates a liquidity trap where early buyers are locked in.

Concentration
Critical

100% of supply in top 10 holders is the most critical risk. This creates: (1) Extreme counterparty risk - any whale can crash price, (2) No organic demand - all price movement is whale-driven, (3) Prisoner's dilemma - whales cannot exit without crashing price, (4) Potential pump-and-dump structure. This level of concentration is typically seen in failed tokens.

Smart Contract
Medium

Security score of 47/100 indicates moderate smart contract risk. While contract is verified, the score suggests potential vulnerabilities. No professional audit mentioned. The extreme concentration creates economic risks beyond code security.

Regulatory
Medium

Healthcare-related tokens face regulatory uncertainty. If PHAI claims to provide medical advice or drug shortage predictions, it may face FDA or healthcare regulatory scrutiny. The token's pharmaceutical focus could attract regulatory attention if it gains traction.

Key Risks

  • •Critical concentration risk: 100% of supply in top 10 holders creates single point of failure and extreme exit liquidity risk. Any coordinated whale exit would crash price 80%+.
  • •Extreme liquidity risk: $49K liquidity is insufficient for meaningful trading. Position sizes above $5-10K will experience severe slippage. This creates a liquidity trap for retail buyers.
  • •Parabolic price action: 263% 24h gain is unsustainable and typically precedes 50-80% corrections. The pattern suggests we may be near a local top.
  • •Zero project traction: No evidence of pharmaceutical partnerships, pilot programs, or real-world implementation. The token is purely speculative with no fundamental support.
  • •Suspicious distribution: 90.5% of holders acquired via transfer (airdrop) rather than organic swaps. Combined with 100% concentration, this suggests potential pump-and-dump structure.
  • •Slowing adoption: Holder growth of only 0.85% in 24h despite 263% price gains suggests the token has reached its distribution targets and is not attracting new organic buyers.
  • •Regulatory uncertainty: Healthcare-related tokens face potential FDA or healthcare regulatory scrutiny if they claim to provide medical advice or shortage predictions.

Mitigating Factors

  • •Real problem statement: The pharmaceutical supply chain inefficiency is documented and genuine, providing potential long-term value if the project can execute
  • •Verified contract: The smart contract is verified on-chain, reducing some smart contract risks
  • •Uniswap v2 infrastructure: Deployed on battle-tested DEX infrastructure rather than custom AMM
  • •Early stage: As an early-stage project, there is potential for significant upside if fundamentals develop

Investor Suitability

PHAI is suitable ONLY for: (1) Experienced cryptocurrency traders with high risk tolerance, (2) Investors who can afford to lose 100% of their investment, (3) Speculators willing to accept extreme volatility and liquidity constraints, (4) Those with conviction in the long-term pharmaceutical supply chain use case and willingness to hold through 80%+ drawdowns. PHAI is NOT suitable for: (1) Conservative investors, (2) Those seeking stable returns, (3) Retail investors with limited trading experience, (4) Anyone who cannot afford to lose their entire investment, (5) Those seeking near-term returns.

Pharmachain AI addresses a genuine $1.65 trillion market problem with documented inefficiencies in pharmaceutical distribution, but currently shows critical structural weaknesses that make it a high-risk speculative asset rather than a sound investment. The token's extreme concentration (100% in top 10 holders), minimal liquidity ($49K), and zero project traction suggest the current price is driven by speculation rather than fundamental value. Success would require the team to demonstrate real pharmaceutical partnerships and user adoption while normalizing holder distribution.

Scenario Analysis

Bull Case
Low

Pharmachain AI successfully partners with major pharmacy networks or healthcare providers and demonstrates real-world utility in optimizing drug distribution. The token gains genuine adoption as a utility token for accessing the platform, driving organic demand. Holder concentration normalizes as retail adoption increases. The token captures a meaningful portion of the $1.65 trillion pharmaceutical market opportunity.

  • +Successful pharmaceutical partnerships with major chains (CVS, Walgreens, etc.) or healthcare systems
  • +Demonstrated reduction in drug expiry losses or improvement in shortage response times
  • +Regulatory approval for healthcare supply chain applications
  • +Organic retail adoption driving holder normalization
  • +Integration with FDA shortage tracking systems
Base Case

PHAI experiences a 50-70% correction from current levels as profit-taking occurs and speculative interest wanes. The token stabilizes at a lower valuation ($15-25K market cap) where it trades based on development progress rather than speculation. The team gradually builds partnerships and demonstrates proof-of-concept, but adoption remains slow due to regulatory barriers and incumbent competition. The token remains a high-risk, low-liquidity asset suitable only for long-term believers in the pharmaceutical supply chain use case.

  • •Parabolic price action is unsustainable and will correct 50-70% in near term
  • •Project team has genuine commitment to pharmaceutical supply chain optimization
  • •Regulatory barriers will slow but not prevent adoption
  • •Holder concentration will gradually normalize as project gains traction
  • •Token will remain illiquid and volatile for 12-24 months
Bear Case
High

The current price is driven by speculative trading and pump-and-dump dynamics rather than fundamental value. Early whales take profits, causing a 70-90% correction. The project fails to demonstrate real traction or partnerships. Holder concentration remains extreme, preventing organic adoption. The token becomes a cautionary tale of speculative excess in crypto markets.

  • -Coordinated whale exit causing liquidity crisis and price collapse
  • -Failure to announce meaningful pharmaceutical partnerships within 3-6 months
  • -Continued extreme holder concentration preventing retail adoption
  • -Regulatory scrutiny on healthcare claims without FDA approval
  • -Competing solutions from established pharmaceutical companies or better-funded startups

Analysis Details

GeneratedMay 2, 2026, 09:01 PM UTC
Data FreshnessReal-time on-chain data as of analysis timestamp
Model Confidence
Medium

Data Snapshot

Price$0.000129437315170733
Market Cap$55.7K
24h Volume$96.5K
Holders4,124
Liquidity$49.2K

Data Sources

On-chain transaction data (buy/sell volumes, transaction counts, unique participants)
Holder distribution analytics (concentration, whale activity, retail participation)
Trading volume metrics (24h, 4h, 1h volume and price changes)
Smart contract analysis (verification status, security score)
Token fundamentals (supply, market cap, project description)

Limitations

  • •Limited historical data: Token appears to be very new with minimal price history, limiting trend analysis reliability
  • •No project metrics: No data on actual pharmaceutical partnerships, user adoption, or real-world implementation
  • •No community data: Follower counts, engagement metrics, and community size not provided
  • •No audit data: No professional smart contract audit report available for security assessment
  • •Incomplete tokenomics: No information on token distribution schedule, vesting, or utility mechanics
  • •Market context limited: Insufficient data on how PHAI correlates with broader crypto market or AI sector
  • •Speculative environment: Extreme price volatility makes any price prediction highly uncertain

How we keep this honest

Every directional call on these pages is recorded before the outcome is known and scored on our public prediction track record. We apply the same standard to others: our audit of 1,581 crypto YouTube predictions found bullish calls did worse than random timing, and our memecoin pump anatomy study measured what chasing a pump actually costs.

Disclaimer: This analysis is for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation to buy or sell PHAI or any other cryptocurrency. Cryptocurrency investments are highly volatile, speculative, and risky. You can lose 100% of your investment. Past performance does not guarantee future results. Always conduct your own research, understand the risks, and consult with a qualified financial advisor before making any investment decisions. The author of this analysis has no financial interest in PHAI and makes no guarantees about the accuracy or completeness of this analysis. Crypto markets are subject to manipulation, fraud, and regulatory changes that could significantly impact token value. Invest only what you can afford to lose completely.

Track PHAI